Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BioMarin Pharmaceutical Inc. before investing.

In this article, we go over a few key elements for understanding BioMarin Pharmaceutical Inc.’s stock price such as:

• BioMarin Pharmaceutical Inc.’s current stock price and volume
• Why BioMarin Pharmaceutical Inc.’s stock price changed recently
• Upgrades and downgrades for BMRN from analysts
• BMRN’s stock price momentum as measured by its relative strength

About BioMarin Pharmaceutical Inc. (BMRN)

Before we jump into BioMarin Pharmaceutical Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Want to learn more about BioMarin Pharmaceutical Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BioMarin Pharmaceutical Inc..

BioMarin Pharmaceutical Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, BioMarin Pharmaceutical Inc.’s stock price was $60.020.

BioMarin Pharmaceutical Inc. is down 0.92% from its previous closing price of $60.580.

During the last market session, BioMarin Pharmaceutical Inc.’s stock traded between $58.920 and $60.800. Currently, there are approximately 192.50 million shares outstanding for BioMarin Pharmaceutical Inc..

BioMarin Pharmaceutical Inc.’s price-earnings (P/E) ratio is currently at 43.0, which is high compared to the Biotechnology industry median of 19. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

BioMarin Pharmaceutical Inc. Stock Price History

BioMarin Pharmaceutical Inc.’s (BMRN) price is currently up 4.89% so far this month.

During the month of July, BioMarin Pharmaceutical Inc.’s stock price has reached a high of $63.050 and a low of $57.250.

Over the last year, BioMarin Pharmaceutical Inc. has hit prices as high as $66.275 and as low as $49.259. Year to date, BioMarin Pharmaceutical Inc.’s stock is up 0.99%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BioMarin Pharmaceutical Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded BioMarin Pharmaceutical Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate BioMarin Pharmaceutical Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BioMarin Pharmaceutical Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

BioMarin Pharmaceutical Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BioMarin Pharmaceutical Inc. (BMRN) by visiting AAII Stock Evaluator.

Relative Price Strength of BioMarin Pharmaceutical Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, BioMarin Pharmaceutical Inc. has a weighted four-quarter relative price strength of -0.64%, which translates to a Momentum Score of 51 and is considered to be Average.

Want to learn more about how BioMarin Pharmaceutical Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BioMarin Pharmaceutical Inc. Stock Price: Bottom Line

As of July 31, 2026, BioMarin Pharmaceutical Inc.’s stock price is $60.020, which is down 0.92% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BioMarin Pharmaceutical Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.